A meta-analysis of prospective and retrospective studies showed a positive association between IGF1 and the risk of prostate cancer but no significant association between IGF2, IGFBP1, IGFBP2, or IGFBP3 and the risk of prostate cancer [94]. Here, IGFBP2 is linked to prostate carcinoma.